ProfileGDS5678 / 1428733_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 89% 86% 88% 87% 90% 86% 85% 87% 84% 84% 86% 83% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6614287
GSM967853U87-EV human glioblastoma xenograft - Control 27.056389
GSM967854U87-EV human glioblastoma xenograft - Control 36.4961186
GSM967855U87-EV human glioblastoma xenograft - Control 46.962588
GSM967856U87-EV human glioblastoma xenograft - Control 56.6871987
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8981690
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3382786
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3303485
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6327487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2548784
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2150884
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5138686
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0152783
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3303185